Ruti Aga's Six Years: Two for a Glucocorticoid, Four for a Forged Prescription

Ten September. Six years. Two for a substance. Four for a piece of paper.

The number being read fastest in the Ruti Aga case is the one being understood least. Four of those six years were not earned on a track or a road. They were earned in a room, during an interview, about a prescription bearing the name of a clinic that does not exist.

The prescription was written by a family member. That person held no medical registration. He said he had used "an old prescription pad from a former workplace." The clinic named on the pad stated plainly that no such pad was ever theirs. Three verification checks. Three failures.

I do not have the case file. I have the Athletics Integrity Unit statement quoted in the source report, the public record, and a habit — putting a count behind every claim. I took the badge at seventeen, so I still watch the first replay as a referee: position first, verdict second. My position here is that I was not on the start list of that half marathon in China, and so this piece will make no claim about how she ran.

Start with what the source withholds. No finishing time for the March race. No splits. No field strength. No number of Ethiopian entrants. Only that she won it and that the sample collected afterwards came back positive. n equals one. One unnamed race, one month, one country. Nothing about form can be derived from that, and I will not try.

The substance is not what it is being called

Methylprednisolone. Most reporting stops at two words — "prohibited steroid." Both words are half-true, and that half-truth props the whole case up in the wrong place.

Methylprednisolone is a glucocorticoid. On the WADA Prohibited List it sits in class S9, not S1. S1 is the anabolic class, the muscle-building class, the one that leads most cleanly to a four-year sanction. What sits in S9 matters, because the answer rewrites the entire architecture of the penalty.

Under the current List, S9 glucocorticoids are prohibited in-competition only, and only by three routes — injection, oral, rectal. Topical creams and several other forms fall outside that scope. A therapeutic knee injection taken out-of-competition is entirely legal. It becomes a violation the moment residues are present in-competition.

A date has to be attached here, because the date is the foundation. In 2026 the List changed and injectable glucocorticoids became strictly prohibited in-competition. Before that, a different regime applied. An athlete who raced on a knee injection in 2026 could not do the same in 2026. The rule moved; the habit did not; that gap is where cases are manufactured.

So the case never hinged on "steroid use." It hinged on route and timing. Where the injection went, and how many days before the race. An athlete with a proper medical file could answer both questions on paper. Aga could not. She had a prescription, and the prescription was false.

A window that opens the night before

Road racing has its own clock. For a road race, the in-competition testing window opens at 23:59 the day before the race. That reads like a technical footnote. It is a trap.

Consider it. A marathoner's knee has been bad for months. The race is four days away. An injection is taken, because it is the cheapest and fastest option available. Four days later the window opens, the sample goes in, and a substance that was medically legitimate was legally required to be absent. The arithmetic is simple and cruel — residue life, injection date, race date. Nobody was adding those three numbers together.

I first understood that window while standing as a sector judge and watching an argument break out over how long a measurement took. That was when it became clear that "when" is often a bigger question than "what." I learned the rulebook first, then I learned where the camera lies — and here, no camera was watching. There was only a laboratory report.

What kind of race it was

A half marathon in China in March. Unnamed. If an AIU test existed there, the race was almost certainly a World Athletics Label event with a genuine elite women's field and in-competition testing. That is an inference, and I will label it as one.

The economics of that tier matter, because this case sits inside them. Between Majors, the Chinese and Gulf label circuit is a separate income floor for East African marathoners. Appearance fees are good, competition is limited, costs are low. For a 2:18–2:20 athlete, the pattern settles into two or three Majors and four or five label races a year. Few starts, large fees, controlled risk.

That same pattern is now the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding in the same races. Where the money is dense, the surveillance will be dense. That is not a prediction; it is bookkeeping.

The record that survives

My notes carry Aga's career as follows — second at Berlin 2026 in roughly 2:18:34, first at Tokyo 2026 in roughly 2:20:40, and three second places at World Marathon Majors. Those figures are not in the source report; they are mine, so treat them as pending verification. The source confirms only the 2026 Tokyo win and the three Major runner-up finishes.

What is confirmed is enough. The 2026 Tokyo title belongs to an athlete who was genuinely elite. The violation is anchored to a March race in a later year. Absent a finding of earlier use, results before that date are not automatically annulled. The source does not state the disqualification scope. That is a gap, and I will call it a gap.

The arithmetic: two and four

The standard sanction for a presence violation is four years. Aga received two. That tells us the panel treated this as a Specified Substance matter and did not find intent. The two-year figure is not a discount; it is a category ruling.

Now look at the other side. If intent was not proven, one route remained open — no significant fault, a further reduction. That route closed. Why? Because the moment a forged prescription entered the file, the argument that the athlete had taken every reasonable precaution collapsed. False documentation does not strengthen a mitigation plea. It strengthens the case against.

Three checks, three failures

What is most technical here is not the substance. It is the verification chain. A prescription can be tested in three places. All three opened. All three shut.

First, the clinic. Does it exist? No. Second, the person. Is he registered? No. Third, the pad. Is it theirs? The clinic denied it outright. Three independent checks, three independent failures.

This is where I have to resist the referee's instinct. From the stands it is easy to declare the whole thing a lie. Where was I standing? Not in that interview room. I have the AIU statement, quoted in paragraphs five and six of the source. What the statement says is my basis. What it does not say is my inference, and labelling inference as inference is the most basic condition of this job.

The four years that came from an interview

The tampering sanction did not arise from a document alone. It arose from an interview — from statements made under questioning. A document can lie once. A statement repeats the lie. When a statement repeats it, the sanction rests on the words, not the paper.

There is a second, less comfortable side to this. AIU interviews with East African athletes are conducted across language and translation conditions that have drawn scrutiny repeatedly. I am not alleging a procedural failure in this case. I am saying that when the largest share of a sanction rests on spoken words, the process behind those words deserves the same scrutiny as their truth.

Backdating is accounting, not clemency

The ban runs from 10 September, and the provisional suspension had already been running from the same date. That is often read as relief. It is not.

Time served under provisional suspension counts against the ban. The athlete gains nothing in real terms; the calendar merely becomes legible. What the source does not say is which year the March race fell in, or which year 10 September refers to. The statement was issued on a Thursday, and the phrasing implies the current year. That is a medium-confidence inference and I will grade it as such. The six-year total does not depend on it.

The road that was open and got closed

Here I invert the case for a moment, because the real lesson sits there.

An athlete, a knee injury, a credentialed team physician. The doctor examines, the injection is decided, the date is recorded, the dose is recorded, the route is recorded. If needed, a TUE application goes in. Even without a TUE, the injection is timed to respect the List's washout conditions. All of it is on paper, and the paper is true.

What is the sanction in that scenario? Nothing. No case exists.

What is the middle scenario? Real records, a timing error. The presence charge becomes arguable, and the outcome could land at a reduced period or a reprimand. The four-year tampering charge never appears, because tampering requires concealment.

The third path is the one taken. The forged document destroyed the only defence that had a genuine chance — route and timing. That is the sharpest paradox in the file. The substance was minor. The defence existed. The sanction became maximal. And the sanction was delivered by the paper, not the molecule.

Scope of disqualification

The source is silent on which results were voided. Standard practice is clear — the competition at which the sample was collected is disqualified, along with its result and its prize money. That means the March half marathon, its title, its prize purse, and ranking points accrued afterwards.

The reverse also needs saying. The 2026 Tokyo title predates that date. Without a finding of earlier use, it stays. That distinction is frequently lost, and it is the distinction between a race-level case and a career-level one.

The appeal window

An appeal to CAS exists, typically within about 21 days of the reasoned decision. But there is a clean technical wall. The substance is arguable. The paper is not. Once the document is established as forged, an appeal must show a procedural defect in the investigation, not that the substance was something other than what was described.

That is why the appeal risk here is live but low-value. Big stake, thin ground.

A comparison the coverage got wrong

Read this case alongside anabolic-steroid cases and the sanction looks disproportionate. Six years? For that? For something with no proven endurance benefit?

But that is the wrong queue. A glucocorticoid case is not a muscle-building case. It is a medical-governance case, in which the question is who wrote what, and who verified it, and when. That is why the weight of the penalty sits on the document.

The substance classification is the legal hinge of this case, and the coverage misread it. If reporting keeps calling it a steroid case, the reader will never understand why a defence was available and why it vanished. In-competition-only prohibition under S9 means the athlete had a legitimate right to argue timing and route. That right was destroyed by the person she trusted.

The replay is not the truth; it is a second angle with its own agenda. There were two replays here. One showed a forged document. The other showed a minor substance. The first one grew, because nobody challenged it.

The proportionality question

I am a counting man, and the count raises an uncomfortable question here. Six years for a glucocorticoid with no established endurance benefit, a drug used daily across sports medicine for knee synovitis. The weight of the sanction is not on the substance. It is on what happened afterwards. That is internally coherent.

What I cannot answer is whether the same file involving a European or American athlete would generate the same public argument. I do not have the comparative dataset. I can register the question, and registering questions is part of the job. In a sport where the East African road-running population is the largest and the medical infrastructure around it the thinnest, the count of sanctions will also be the largest. That cannot be bias. It also cannot be something we simply decline to look at.

Where the enforcement frontier moved

The biggest signal here is not in the sanction. It is in what the sanction is made of. Two years from a molecule. Four from a document.

That is a shift. The old anti-doping front was detection. The new one is verification. The question used to be what was in the body. Now it is what is on the paper and who wrote it. The shift is technical, but its effect on sanction length is direct, because lying on paper costs more than a residue in a sample.

I expect more cases in the next two seasons where the primary charge is documentary rather than pharmacological. I am tracking that number. It is not a prediction; it is a column I have opened in my sheet.

The real root cause is an absence

Ask me what caused this and I will not name a substance. I will name an absence.

There was no credentialed team physician. The person who wrote the prescription was a family member with no registration. That is not a filing error. It is the signature of an athlete making the most technical decision of a career on the strength of an informal network.

And that network did not appear overnight. In marathon running, injury is a cost. Knee, Achilles, calf — the parts that absorb 180 kilometres a week. When injury arrives there are two paths. Stop, treat, document, wait. Or damp the inflammation and stand on the line.

The second path is faster. The second path pays. Appearance money lands on the day you start. That incentive structure is wrong, and it belongs to the system, not the athlete. The forged prescription is the waste that flows underneath it.

Language, translation, and an uncomfortable count

I should state my position plainly, because that is the job. I hold no mixed-zone bib for this story. I was not in that interview room. My access is the AIU statement as printed in the source report, and the public record.

I keep a column in my sheet — questions left unanswered by a federation or an agency. In this case my notebook currently holds seven. Which race was it. What was the time. What is the disqualification scope. Was prize money recovered. Was the agent or management investigated. What did the Ethiopian federation say. What language was the interview conducted in.

Seven. I write the number because a number is harder to soften than a paragraph.

The landscape did not move; the governance did

On Ethiopian women's marathon depth, one fact is clear. Removing a 2:18–2:20 athlete changes nothing in national selection arithmetic. The depth is such that the next name simply steps up.

That sounds harsh. It is also the count. And the real significance of this case sits inside it. The sporting map did not change. The governance map did. The question is not that Ethiopia lost one runner. It is how many more runners the same mechanism can reach.

Fourteen Chennai fixtures taught me that a quiet whistle is still a decision. This is that whistle. No noise, no scoreboard change, no medal stripped. Just a date entered — 10 September — and a career closed.

What to count next

First count — how many road-running cases in the next two seasons begin with a substance and end with a document. If that number climbs, the problem is paper, not pharmacology.

Second count — how many federations run a TUE desk for their athletes. One room, one form, one person who knows what sits in S9. It is not expensive. Not having it is.

Third count — how many athletes can say, in writing, how many days before their last race an injection went into their knee. That question should be asked of every athlete, every season, on a form. Anyone without an answer is standing on this case's road.

One question I cannot answer

If she had held a real prescription that day — a real clinic, a real doctor, a real date — would we be reading this piece at all?

Probably not. And that is the most uncomfortable fact in the file. Six years were not imposed by a substance. They were imposed by the absence of anyone around her who could explain what route and timing mean in law.

The next time a road runner stands on a start line with a knee injection, the question will not be whether the knee is sound. It will be whether the paper is. And that question will not be settled in a laboratory. It will be settled in a call room, four days before the race, when someone decides whether the injection goes in today or next month.